

AMENDMENTS TO THE CLAIMS

Amendments to the claims are reflected in the following listing of claims, which replaces all prior versions or listings of claims:

1. (Currently amended) A method for the detection of the presence of or the risk of breast cancer in a patient comprising the steps of: (i) isolating a sample of the patient's genome; and (ii) detecting ~~the presence or~~ the level of expression of the gene comprised within the sequence identified herein as SEQ ID No. 1, wherein ~~the presence or increased~~ expression of the gene in the sample, compared to the level of expression of the gene in normal control breast tissue, indicates the presence of or the risk of breast cancer.
2. (Original) A method according to claim 1, wherein the gene is that identified as SEQ ID No. 2.
- 3-4. (Cancelled)
5. (Currently amended) A method according to claim 1, wherein detection is carried out by amplifying messenger RNA, or cDNA synthesized therefrom, ~~the~~ gene using ~~a~~ the polymerase enzyme.
6. (Withdrawn) An isolated polynucleotide comprising the nucleotide sequence identified herein as SEQ ID No. 1, or its complement, or a polynucleotide of at least 15 consecutive nucleotides that hybridises to the sequence (or its complement) under stringent hybridising conditions.
7. (Withdrawn) An isolated polynucleotide according to claim 6, wherein the sequence is that identified herein as SEQ ID No. 2.
8. (Currently amended) A method according to claim 1 wherein the detecting comprises performing an *in vitro* hybridization assay with the sample of the patient's genome and an isolated polynucleotide comprising at least 15 consecutive nucleotides of SEQ ID No. 1, or its complement, as a hybridization probe to detect the level of expression of the gene ~~presence of or the risk of cancer in the patient~~.

9. (Cancelled)

10. (Withdrawn) A peptide comprising the sequence identified herein as SEQ ID No. 3, or a fragment thereof of at least 10 consecutive amino acid residues.

11. (Withdrawn) An antibody having an affinity of at least 10^{-6} M for the peptide of claim 10.

12. (Withdrawn) Use of a second polynucleotide that hybridises with or inhibits the expression of an endogenous gene that comprises the polynucleotide of claim 6 or claim 7, in the manufacture of a medicament for the treatment of cancer, in particular breast cancer.

13. (Withdrawn) Use according to claim 12, wherein the gene comprises the polynucleotide of claim 7.

14. (Currently amended) A method according to claim 1 wherein the detecting comprises performing an *in vitro* hybridization assay with the sample of the patient's genome and an isolated polynucleotide comprising at least 15 consecutive nucleotides of SEQ ID No. 2, or its complement, as a hybridization probe to detect the level of expression of the gene ~~presence of or the risk of cancer in the patient~~.

15. (Cancelled)